CDC Warns of Severe Mosquito-Borne Disease Risk for Patients on B-Cell Therapies
CDC issues health advisory on severe arboviral disease risk for patients on B-cell depleting or modulating medications.
The US Centers for Disease Control and Prevention (CDC) has issued a health advisory concerning the risk of severe arboviral disease in patients undergoing treatment with B-cell depleting or modulating medications. These therapies, which target a type of immune cell, may leave individuals more vulnerable to severe outcomes from infections transmitted by mosquitoes and ticks.
The advisory highlights a significant gap in medical countermeasures. According to the CDC, there are currently no approved treatments, prophylactic agents, or human vaccines available to prevent the arboviral diseases that are endemic within the United States. This means that for patients in this category, the primary defense relies on preventive measures against vector bites.
Arboviral diseases, which include infections like West Nile virus and dengue, can range from mild febrile illness to severe neurological complications. The CDC's alert underscores the need for heightened clinical vigilance and proactive patient counseling for those on these specific therapies, particularly during peak transmission seasons.